glp 1 in heart failure The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 receptor agonist-based therapies and
Description
3 Currently, three GLP-1s have been approved in the U.S
Endocrinology 140: 1132-1140, 1999
Pi-Sunyer, Xavier, et al
Cardiovascular outcome trials CVOTs have emerged as a pivotal component of assessing the impact of GLP-1 receptor agonists on cardiovascular health ( GLP-1 receptor agonists have demonstrated unique properties beyond glucose regulation
This ratio corresponds well with the almost 2-fold increase in -cell mass in Cre Ex + mice discussed above
